Medivation Announces Treatment of First Patient in Phase 1-2 Clinical Trial of MDV3100 in Hormone-Refractory Prostate Cancer

Medivation Announces Treatment of First Patient in Phase 1-2 Clinical Trial of MDV3100 in Hormone-Refractory Prostate Cancer: "SAN FRANCISCO, July 25 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced treatment of the first patient in a Phase 1-2 clinical trial evaluating MDV3100, the Company's lead development candidate for hormone-refractory prostate cancer."